Halo of prostate cancer cells holds key to diagnosing disease

February 13, 2013, University of St Andrews

Men thought to have prostate cancer could receive a more accurate diagnosis thanks to a simple genetic test, research has shown.

The procedure will help identify cancer that is missed in routine check-ups, and will save patients undergoing repeated invasive investigations that carry a risk of infection.

Scientists from the Universities of Edinburgh and St Andrews, who led the research, say the improved test works by recognising the "halo" of cells that form around a .

These cells, which can appear healthy under a microscope, contain silenced genes that turn off the cell's natural protection against growth.

The study was carried out by Dr Grant Stewart, a Clinical Lecturer in Urology at the University of Edinburgh with David Harrison, who is now Professor of Pathology at the University of St Andrews.

The researchers say that by identifying in these halo cells, they can tell that a patient is more likely to have a tumour, even if their tissue sample shows no .

Dr Stewart commented, "Prostate cancer is the most common cancer for men in the UK – although it can be challenging to diagnose as these tumours are not easily seen on scans. Our work shows that there is a more precise way of detecting these cancers. This new test helps us to see the ripple effect of a tumour so that even if the cells we examine aren't cancerous, we can tell there might be a tumour nearby."

More than one in ten men tested for prostate cancer receives an inconclusive result and has to have a second biopsy – which can be painful and carries a risk of serious infection.

This is often because the first tissue sample taken is clear, while their blood test reveals high levels of the PSA protein – prostate-specific antigen – which is associated with prostate cancer.

The team examined from some 500 men who had undergone a prostate check-up and received inconclusive results.

The new test correctly identified hidden tumours in seven out of 10 cases – without the need for a second biopsy.

The test was also 90 per cent effective in showing which patients did not have . It provided peace of mind to those without the disease, and prevented two-thirds of men from undergoing a second, unnecessary biopsy.

The test – developed in partnership with diagnostics firm MDxHealth – is now available in the US. The team hopes to work with the NHS to introduce it into routine prostate checks in the UK.

Professor Harrison, who is also Director of Laboratory Medicine for NHS Lothian, commented, "Accurate and timely diagnosis is the most important part of the patient journey in cancer. Anything that can reliably reduce that period of uncertainty before effective treatment begins is to be welcomed."

Explore further: PSA test valuable in predicting biopsy need, low-risk prostate cancer

Related Stories

PSA test valuable in predicting biopsy need, low-risk prostate cancer

October 21, 2011
The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. ...

New prostate cancer test could change treatment

February 8, 2013
Thousands of men face a prostate biopsy following higher-than-normal results from their annual prostate-specific antigen (PSA) test, the traditional screening for prostate cancer. But recent studies have shown three in four ...

Personalised prostate cancer screening may save thousands from unnecessary treatment

November 5, 2012
Targeting prostate cancer screening based on a man's age and genes could potentially save thousands of men from unnecessary treatment and save the NHS millions of pounds. The research is presented at the NCRI Cancer Conference ...

New prostate cancer test gives more accurate diagnosis

April 6, 2011
In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer -- particularly the aggressive form of the disease -- and substantially reduced false ...

Recommended for you

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.